Fortress Biotech, Inc. (FBIO)
Market Cap | 34.09M |
Revenue (ttm) | 85.11M |
Net Income (ttm) | -62.86M |
Shares Out | 20.41M |
EPS (ttm) | -6.10 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 109,072 |
Open | 1.660 |
Previous Close | 1.690 |
Day's Range | 1.620 - 1.680 |
52-Week Range | 1.240 - 10.350 |
Beta | 1.67 |
Analysts | Strong Buy |
Price Target | 12.50 (+648.5%) |
Earnings Date | Aug 12, 2024 |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and ... [Read more]
Financial Performance
In 2023, FBIO's revenue was $84.51 million, an increase of 11.58% compared to the previous year's $75.74 million. Losses were -$68.67 million, -27.42% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 648.50% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/m/3/press3-2506342.jpg)
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has ente...
![](https://cdn.snapi.dev/images/v1/6/n/press17-2506157.jpg)
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has comp...
![](https://cdn.snapi.dev/images/v1/k/a/press7-2492498.jpg)
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reac...
![](https://cdn.snapi.dev/images/v1/m/r/press2-2434517.jpg)
Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...
![](https://cdn.snapi.dev/images/v1/y/l/press1-2433380.jpg)
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025
![](https://cdn.snapi.dev/images/v1/m/2/press14-2433252.jpg)
Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on...
![](https://cdn.snapi.dev/images/v1/u/s/press20-2429330.jpg)
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV
![](https://cdn.snapi.dev/images/v1/0/a/press7-2428000.jpg)
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% in...
![](https://cdn.snapi.dev/images/v1/0/i/conf17-2426900.jpg)
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James O...
![](https://cdn.snapi.dev/images/v1/k/0/press3-2423907.jpg)
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial re...
![](https://cdn.snapi.dev/images/v1/u/b/conf11-2414621.jpg)
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...
![](https://cdn.snapi.dev/images/v1/g/z/press2-2404133.jpg)
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on...
![](https://cdn.snapi.dev/images/v1/w/d/conf14-2391001.jpg)
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses ...
![](https://cdn.snapi.dev/images/v1/n/j/press10-2347152.jpg)
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing...
![](https://cdn.snapi.dev/images/v1/g/7/press14-2337320.jpg)
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial ...
![](https://cdn.snapi.dev/images/v1/j/u/press17-2336254.jpg)
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022
![](https://cdn.snapi.dev/images/v1/7/o/press17-2328674.jpg)
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024 Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024
![](https://cdn.snapi.dev/images/v1/r/b/conf13-2326384.jpg)
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...
![](https://cdn.snapi.dev/images/v1/1/2/press18-2322087.jpg)
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling an...
![](https://cdn.snapi.dev/images/v1/j/w/press12-2319875.jpg)
Fortress Biotech to Participate in 36th Annual ROTH Conference
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing o...
![](https://cdn.snapi.dev/images/v1/6/h/press14-2317709.jpg)
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues
![](https://cdn.snapi.dev/images/v1/b/g/press8-2306193.jpg)
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for Menkes disease
![](https://cdn.snapi.dev/images/v1/7/r/press19-2218072.jpg)
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea
![](https://cdn.snapi.dev/images/v1/k/r/press8-2215411.jpg)
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...
![](https://cdn.snapi.dev/images/v1/q/h/press15-2213766.jpg)
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29 Provides additional capital for general corporate purposes including funding to s...